Wechat

Website

Chinese Journal of Oncology Prevention and Treatment ›› 2021, Vol. 13 ›› Issue (6): 629-634.doi: 10.3969/j.issn.1674-5671.2021.06.10

Previous Articles     Next Articles

Analysis of cancer mortality trend of urban residents in Shenyang,2013—2017

  

  • Online:2021-12-25 Published:2022-01-07

Abstract: Objective To analyze the cancer mortality and its changing trend for the urban residents in Shenyang from 2013 to 2017.  Methods The death data of malignant tumors were extracted from the follow-up registration of tumors in Shenyang, to calculate the crude mortality, standardized rate (Chinese standard population, ASR China), age-specific mortality, cumulative mortality (0-74 years old), and truncated mortality (35-64 years old). The χ2 test was performed on the mortalities of male, female and all age groups by SPSS 23.0 software; The death trend was analyzed by the Joinpoint 3.5.3 software. Results From 2013 to 2017, the crude mortality rate of malignant tumors for the urban residents in Shenyang was 222.16/105, the ASR China was 100.50/105, and the cumulative rate (0-74 years old) was 10.88%. The standardized mortality of malignant tumors and male standardized mortality of malignant tumors during the 5 years showed a downward trend (APC=-1.77%, P=0.030; APC=-1.78%, P=0.020) , and the crude mortality rate of malignant tumor was higher in males than in females (χ2=1, 512.28, P<0.001); The top five mortality rates of malignant tumors were lung cancer, liver cancer, colorectal cancer, gastric cancer and esophageal cancer in male, while the top five mortality rates of female malignant tumors were lung cancer, colorectal cancer, breast cancer, liver cancer and gastric cancer. Conclusions From 2013 to 2017, the mortality rate of malignant tumor for the urban residents in Shenyang decrease. The major types of cancer for prevention and control include lung cancer, breast cancer, liver cancer, colorectal cancer, gastric cancer and esophageal cancer.

Key words: Malignant tumor, Mortality rate, Trend, Prevention and treatment strategy

CLC Number: 

  • R73-31